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Abstract
The high prevalence of nasopharyngeal cancer (NPC) in Southern Asia and Mediterranean
Northern Africa suggests genetic predisposition among other factors. While Human Leukocyte
Antigen (HLA) haplotypes have been conclusively associated with NPC predisposition in Asians,
Northern African Maghrebians have been less intensely studied. However, low resolution
serological methods identified weak positive associations with HLA-B5, B13 and B18 and a negative
with HLA-B14. Using sequence based typing (SBT), we performed a direct comparison of HLA class
I frequencies in a cohort of 136 Tunisian patients with NPC matched for gender, age and
geographical residence to 148 normal Tunisians. The bimodal age distribution of NPC in
Maghrebians was also taken into account. HLA frequencies in normal Tunisians were also
compared with those of Northern Moroccan Berbers (ME) to evaluate whether the Tunisian
population in this study could be considered representative of other Maghrebian populations. HLA-
B14 and -Cw08 were negatively associated with NPC (odd ratio = 0.09 and 0.18 respectively, Fisher
p2-value = 0.0001 and = 0.003). Moreover, positive associations were observed for HLA-B-18, -
B51 (split of -B5) and -B57 (p2-value < 0.025 in all) confirming previous findings in Maghrebs. The
HLA-B14/Cw*08 haplotype frequency (HF) was 0.007 in NPC patients compared to 0.057 in both
Tunisian (OR = 0.12; p2-value = 0.001) and Moroccan controls. This study confirms several
previous associations noted by serologic typing between HLA class I alleles and the prevalence of
NPC in Maghrebians populations. In addition, we identified a putative haplotype rare in Tunisian
patients with NPC that may serve as a genetic marker for further susceptibility studies.
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Background
The prevalence of Epstein-Barr virus (EBV)-associated
anaplastic nasopharyngeal carcinoma (NPC) might be
partially dependent upon genetic background affecting
predominantly certain ethnic groups1. Among them,
some regions of Southern Asia suffer about a 100-fold
higher prevalence compared with populations not at risk
and this high prevalence is maintained upon immigration
to Western Countries such as in the U.S. Chinese popula-
tion Northern African populations (Algerians, Moroccans
and Tunisians) referred to as Maghrebians also suffer
increased prevalence of NPC which persists upon migra-
tion to low risk areas [1,2] Although heterogeneity of viral
strains, dietary, environmental and socio-economical var-
iables have been implicated as predisposing factors, it is
likely that genetic traits play a significant role at least in
Asians [3,4].
Genetic predisposition of NPC is paralleled by a strong
associations with some HLA class I alleles which have
been extensively studied in the Asian population. Of
them, HLA-A2, -B14, -B46 and -B58 predispose to the dis-
ease while HLA-A11 exercises a protective effect in Asians
[5-12] Moreover, a meta-analysis confirmed a consistent
association between HLA-A2, A11, B14, B46 and NPC
[13]. With few exceptions [10,11]., most studies
employed serologic HLA typing methods that cannot dis-
criminate alleles within large serologic families [14]. Such
discrimination, however, is critical since different ethnic
groups display significant differences in frequency of HLA
alleles within a serologic family with different capacity to
bind and present epitopes that may be relevant to the
immune defense against EBV-coded or other NPC-associ-
ated antigens. For instance, the HLA-A2 serologic family
includes about 100 alleles [15] whose distribution is dif-
ferent among ethnic groups with HLA-A*0201 (~90%)
and HLA-A*0205 (~5%) predominant among Caucasian
and HLA-A*0203 (~20%) -A*0206 (~15%) and -A*0207
(~40%) in Asians [16-19] Interestingly, sequence based
typing (SBT) in Taiwanese identified a positive association
between HLA-A*0207 (but not other HLA-A2 subtypes)
and NPC [10]. This association was particularly strong
when the observation was extended to the HLA-A*0207/
B*4601 haplotype. Since, chromosome 6p, in particular
6p21-23, is characterized by unusually high gene density
harboring gene clusters coding for several protein families
besides HLA molecules [20], it remains unclear whether
NPC/HLA associations reflect distinct antigen presenta-
tion potentials of various alleles or rather represent a
marker for a susceptibility/protection locus in strong link-
age disequilibrium with the HLA region [21].
Maghrebian populations have been less intensely studied
at high-resolution SBT. Serological analyses reported pos-
itive associations between NPC and HLA: these included
increased frequency of HLA-B5 in Algerians (38.2% vs
24.4%) [22], HLA-B13 in Tunisians (15.5% vs 4%) [23]
and HLA-B18 in Moroccans, of which only the last was
significant after correction for number of specificities
tested (relative risk = 4.14) [24]. In 1983, Heirat P et al.
[22] reported in a cohort of patients with NPC from Alge-
ria a lower frequency of HLA-Aw33 (3.9% vs 16.8%), -B14
(1.3% vs 16%) and -DR4 (13.2% vs 29.1%) in NPC com-
pared with matched controls. After correction for the
number of specificities tested, these differences were not
statistically significant and were not pursued further. Sub-
sequently, HLA-A*3301 and HLA-B*1402 were found to
belong to the same ancestral haplotype [25]. Further stud-
ies done in other Maghrebians did not reproduce these
findings. Independently, Mokni-Baizig N et al. [23] noted
that the HLA-A23 allele was absent in NPC patients com-
pared to an 18% frequency in non tumor-bearing Tuni-
sians. This is interesting because HLA-A23 is part of an
African extended haplotype that includes a -B14 allele
(HLA-A*2301/HLA-B*1403) [26]. Moreover, Dardari R et
al. [24] reported a significantly lower frequency of HLA-
A9 serologic family alleles in NPC patients compared with
controls. Since the HLA-A9 serologic family includes HLA-
A23, this observation suggests that the reduced frequency
of HLA-A9 reflects a lower frequency of the HLA-A*2301/
HLA-B*1403 haplotype. Thus, previous studies in Magh-
rebians suggest that HLA-B14 and HLA-A alleles linked to
the HLA-B14 serological family may be under-represented
in patients with NPC compared with normal controls.
Conversely, HLA-B5, -B13 and -B18 could be associated
with increased risk of NPC.
Molecular typing provides enhanced discrimination for
population studies and large data bases have accumulated
in African populations including Maghrebians [25-29]
These studies, however, did not include Tunisians (TU).
Therefore, the aim of this study was to 1) establish a high
resolution SBT data base in normal Tunisians matched for
gender, age and geographical residence to a similar cohort
of NPC patients; 2) compare HLA allele and haplotype
frequencies between normal healthy Tunisians and the
previously characterized Northern Moroccan Berber pop-
ulation (ME) [28] to provide a broader frame for the inter-
pretation of the results from the Tunisian study; 3) test the
validity of the reported decreased prevalence of HLA-B14
and increased prevalence of HLA-B5, -B13 and -B18 in
patients with NPC based on SBT-derived, high resolution
information; 4) Find novel alleles and haplotypes associ-
ated with NPC in Tunisian that may serve as putative
genetic markers for further susceptibility studies.
Materials and methods
Study population
147 Patients with undifferentiated nasopharyngeal carci-
noma were recruited from the Department of RadiationJournal of Translational Medicine 2007, 5:22 http://www.translational-medicine.com/content/5/1/22
Page 3 of 13
(page number not for citation purposes)
Oncology of Sousse Hospital, between 1991 and 2004.
The patients with nasopharyngeal cancer had a mean age
of 41.5 ± 16 years. The clinical stages ranged from II to IV
(TNM classification, 1987). The diagnosis of cancer was
confirmed by histopathology analyses. The histology was
undifferentiated carcinoma (type III, WHO classification)
in all cases [30,31].
Patients were age and sex matched with 150 control sub-
jects and selected from the same population living in the
middle coast of Tunisia sharing the same environmental
conditions. Control subjects having a mean age of 40 ±
12.5 years were healthy blood donors having no evidence
of any personal or family history of cancer (or other seri-
ous illness). In order to respect the Hardy-Weinberg con-
ditions highly stringent criteria were used for recruitment.
To avoid any consanguinity bias, both patients and con-
trol groups were formed with unrelated individuals.
The control Tunisian population data were also compared
to an available database of SBT typing performed in a pop-
ulation from North Morocco [28] to provide a frame of
reference for this study in the context of other previously
studied Maghrebian populations.
Specimen collection, preparation and HLA genotyping
Blood samples were obtained from all subjects consenting
to the collection of blood, [0] through venipuncture and
processed for DNA preparation. Extracted DNA was
shipped to the Department of Transfusion Medicine, Clin-
ical Center; National Institutes of Health where the geno-
typing was performed. SBT of HLA class I loci was
performed as previously described [32]. The primary PCR
amplification reaction produced a 1.5 kb amplicon
encompassing exon 1 through intron 4 of the HLA class I
locus. All reagents necessary for primary amplification
and sequencing were included in the HLA-A, HLA-B and
HLA-C allele SEQR Sequenced Based Typing Kits (Abbott
Diagnositics, Abbott Park, IL U.S.A.). After the primary
amplification PCR products were purified from excess
primers, dNTPs and genomic DNA using ExoSAP-IT
(American Life Science, Cleveland, OH, U.S.A.). Each tem-
plate was sequenced in the forward and reverse orienta-
tion for exon 2, exon 3 and exon 4 according to protocols
supplied with the SBT kits. Excess dye terminators were
removed from the sequencing products utilizing an etha-
nol precipitation method with absolute ethanol. The reac-
tion products were reconstituted with 15 μl of Hi-
Di™Formamide (PE Applied Biosystems/Perkin-Elmer,
Foster City, CA, U.S.A.) and analyzed on the ABI Prism*
3700 DNA Analyzer with Dye Set file: Z and mobility file:
DT3700POP6 [ET].
Statistical analysis
SBT information was used to compare our data base with
recent reports on the prevalence of HLA alleles and haplo-
types in African populations [25-29] The Hardy-Weinberg
equilibrium was tested using the Guo and Thomson
method [33], and gene diversity was estimated by maxi-
mum likelihood at each locus. Haplotype frequencies
(HF) were estimated using an expectation-maximisation
(EM) algorithm for multi-locus genotypic data when the
gametic phase is not known employing the Arlequin pop-
ulation genetic software v3.01 [34,35] The Ewens-Watter-
son homozygosity test [36,37] was used to examine the
presence of selective forces influencing allelic diversity at
each locus (balancing selection or directional selection).
The significance was calculated by using the Ewens-Wat-
terson test and Slatkin exact test [38,39]. HLA class I allele
frequencies between Tunisians and Moroccans were com-
pared using a χ2 analysis with Bonferroni correction. HLA
class I (haplotipic) genetic diversity between the 2 popu-
lations was assessed by computing Fst genetic distance
and the exact test of population differentiation using Arle-
quin. The most frequent 2 loci (Cw-B, A-Cw, A-B) and
class I (A,-Cw,-B) haplotypes were described. Linkage dis-
equilibrium (D) and relative D (D') between two alleles at
two different loci and their level of significance (p) for 2 ×
2 comparisons were calculated [40].
Comparisons between NPC and controls were performed
first at the low resolution (two digit discrimination level)
to compare our results with previously reported informa-
tion based on low resolution serological typing. For this
descriptive analysis data were simply compared using a 2
× 2 comparison without correction for number of tests.
Further, SBT based comparisons between NPC and con-
trol populations were performed using allele frequencies
and haplotypes calculated with the statistical tests dis-
cussed in the previous paragraph.
Results
HLA frequencies among non-tumor bearing healthy 
Tunisians (TU)
To our knowledge no reports are available on SBT-defined
HLA class I frequencies among healthy Tunisians. How-
ever, extensive information exists on other African/Magh-
rebian populations [25-29] We, therefore, first analyzed
HLA class I frequencies in Tunisian in the context of avail-
able information in other Maghrebian populations. In
particular, we performed a direct comparison with Pianc-
atelli D. et al [28] SBT data on Moroccans.
Of the 150 samples obtained from normal control sub-
jects only 147 HLA-A, 148 HLA-B and 147 HLA-Cw locus
typings could be performed due to insufficient quantity or
quality of the recovered genomic DNA in the remaining
cases. Because of the recognized bimodal age distributionJournal of Translational Medicine 2007, 5:22 http://www.translational-medicine.com/content/5/1/22
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of NPC in Tunisia an effort was made to collect DNA rep-
resentative of all age groups in the control population
(Figure 1). The allele and haplotype frequencies for the
HLA class I loci in the Tunisian population compared to
Moroccan are reported in Tables 1, 2, 3. The Tunisian pop-
ulation was in Hardy-Weinberg equilibrium for all loci
(HLA-A, p = 0.568 ± 0.000; HLA-B, p = 0.505 ± 0.000;
HLA-Cw, p = 0.297 ± 0.000); the allelic distribution
showed a very high level of gene diversity: HLA-A 0.94;
HLA-B 0.96 and HLA-Cw 0.90. In the Moroccan popula-
tion, these values were slightly lower for HLA-A (0.92)
and HLA-B (0.95), and not different for HLA-Cw. Popula-
tion comparisons showed that the two populations were
not significantly different (Fst p value: 0.189) and no sta-
tistically significant differences were observed in allele fre-
quencies between the two populations (Table 1).
By comparing in Tunisians the observed homozygosity F
values with those expected under the Ewens-Watterson
neutral model, a tendency toward balancing selection was
observed, (observed F less than that expected under neu-
trality) although no significant difference in homozygos-
ity was found (A locus: observed F: 0.068; expected F:
0.090; B locus: observed F: 0.048; expected F: 0.056; Cw
locus: observed F: 0.101; expected F: 0.124).
Single locus analysis
A total of 35 HLA-A, 51 HLA-B and 24 HLA-Cw alleles
were observed in Tunisians. The most frequently detected
A: age distribution of the 136 patients with NPC whose DNA was a sufficient quality to yields informative typing results Figure 1
A: age distribution of the 136 patients with NPC whose DNA was a sufficient quality to yields informative typing results. Age is 
shown in 5 years brackets to underline the bi-modal distribution of NPC prevalence in Tunisian reflected by the population 
studied. B: Age distribution of patients with NPC (black bars) and normal TU controls (white bars) separated according to rec-
ognized brackets of prevalence: precocious NPC (10 to 25 years), middle age NPC (26 to 50) and late onset NPC (> 50 years 
of age) (lower panel). C: age distribution of patients with NPC and normal TU controls according to age and gender.
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Table 1: HLA-A, -B and -Cw allele frequencies in ME and TU
HLA-A allele (ME n = 73; TU n = 147)
ME TU ME TU ME TU
A*010101 0.137 0.088 A*110101 0.048 0.030 A*3301 0.055 0.031
A*0102 0 0.003 A*2301 0.082 0.078 A*3303 0 0.01
A*0103 0 0.007 A*240201 0.062 0.037 A*33new* 0 0.003
A*020101 0.178 0.173 A*250101 0.007 0.007 A*3402 0.021 0.01
A*0202 0 0.034 A*2601 0.007 0.031 A*3601 0 0.003
A*0205 0 0.024 A*2902 0.041 0.061 A*6601 0.021 0.02
A*0212 0 0.003 A*3001 0.014 0.031 A*680101 0.021 0.031
A*0285 0 0.003 A*3002 0.089 0.044 A*680102 0.021 0.014
A*02new* 0 0.003 A*3004 0.007 0.003 A*680201 0.048 0.054
A*030101 0.034 0.068 A*3010 0 0.003 A*7401 0.014 0.003
A*030103 0 0.003 A*310102 0.021 0.024 A*8001 0 0.007
A*0302 0.041 0.017 A*3201 0.034 0.034
HLA-B allele (ME n = 69; TU n = 148)
ME TU ME TU ME TU
B*070201 0.022 0.041 B*3508 0 0.014 B*4901 0.051 0.027
B*0705,06 0.007 0.003 B*3701 0.007 0.007 B*5001 0.073 0.139
B*0801** 0.087 0.064 B*3801 0.014 0.020 B*5002 0.043 0.014
B*1302°° 0 0.017 B*390602 0 0.003 B*510101,02 0.043 0.054
B*1401 0.014 0.010 B*3910 0.007 0.007 B*5108 0 0.003
B*1402 0.036 0.054 B*3920 0 0.003 B*520101,02 0.007 0.024
B*1403 0 0.010 B*4001 0 0.010 B*5301^^ 0.014 0.024
B*150101 0 0.014 B*4002 0.007 0.003 B*5303 0 0.003
B*1503 0.014 0.017 B*4101 0 0.017 B*53new* 0 0.003
B*1510 0 0.004 B*4102 0.065 0.020 B*5501 0 0.003
B*1516 0 0.017 B*4201 0 0.017 B*570101 0.014 0.003
B*151701 0 0.007 B*4202 0.007 0.007 B*5702 0 0.003
B*180101 0.051 0.023 B*4402 0.094 0.047 B*570302 0.007 0
B*2702 0.007 0.007 B*440301 0.116 0.071 B*5801 0.014 0.027
B*2703 0.007 0 B*440302 0.007 0 B*5802 0.007 0.003
B*2705,13^ 0.021 0.010 B*4405 0 0.003 B*7301 0 0.007
B*350101,42 0.043 0.027 B*4427 0 0.007 B*7801 0.014 0
B*3502 0.007 0.017 B*4501 0.043 0.047
B*3503 0.014 0.014 B*470101 0.007 0.003
HLA-Cw allele (ME n = 63; TU n = 147)
ME TU ME TU ME TU
Cw*0102 0 0.007 Cw*0602 0.183 0.218 Cw*140201 0.008 0.027
Cw*020202*** 0.095 0.054 Cw*0701,06° 0.183 0.129 Cw*150201 0.016 0.034
Cw*0210 0.016 0.017 Cw*070201 0.032 0.054 Cw*150501,02 0.016 0.014
Cw*0302 0 0.010 Cw*0704,0711 0.016 0.010 Cw*1601 0.032 0.044
Cw*030301 0 0.003 Cw*0802 0.056 0.058 Cw*1602 0.016 0.007
Cw*030401, 02°°° 0 0.014 Cw*120201,02 0.008 0.024 Cw*160401 0 0.003
Cw*040101 0.159 0.126 Cw*120301 0.008 0.044 Cw*1701,02,03^^^ 0.071 0.051
Cw*0501,03 0.087 0.048 Cw*12new* 0 0.003
Alleles having a frequency > 5% are in bold. °Including Cw*070101,02; **Two samples in this group were assigned as B*080101; °°One sample in 
this group was assigned as B*130201; ^Two samples in this group were assigned as B*270502 (1ME, 1TU); ^^Two samples in this group were 
assigned as B*530101; ***One sample in this group was assigned as Cw*0202; °°°One sample in this group was assigned as Cw*0304; ^^^Cw*1703, 
af = 0.063 in ME.
Not discriminated alleles due to polymorphisms outside the assayed exons are listed separated by ",". Nomenclature was updated until the sixth 
digit; seventh and eighth digits were not included in the table. In case of ambiguous allele combinations, the most frequent allele combination was 
included in the analysis.
No statistically significant differences were identified in any comparison between the Tunisian and Moroccan cases.Journal of Translational Medicine 2007, 5:22 http://www.translational-medicine.com/content/5/1/22
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alleles in Tunisians and Moroccans were: HLA-
A*020101(TU:17.3%, ME:17.8%), A*010101 (TU:8.8%,
ME:13.7%), A*2301 (TU:7.8%, ME:8.2%), HLA-
B*5001(TU:13.9%, ME:7.3%), B*440301(TU:7.1%,
ME:11.6%), B*0801(TU:6.4%, ME:8.7%), HLA-
Cw*0602(TU:21.8%, ME:18.3%), Cw*040101
(TU:12.6%, ME:15.9%) and Cw*07 group (TU:19.3%,
ME:18.4%).
Noteworthy was the presence of rare alleles in Tunisians,
as classified according to the National Marrow Donor Pro-
gram [41], such as B*5303 (originally identified in His-
panics but present also in Africans and Caucasians) and
A*0285 (Caucasian) and uncommon alleles present in
Africans, such as A*3010 (identified in Moroccans),
A*0103, A*3004, A*3601, A*8001, B*1403, B*4202,
B*5702, Cw*0210 (present in Moroccans), A*030103,
B*4405, B*4427, B*5108, B*7301, Cw*1604 (present in
Caucasians), A*0212, B*390602, B*5303 (present in His-
panics) and B*3920 (present in Blacks). Although not sig-
nificant, a lower frequency of B*44, with a wider number
of alleles (some of which uncommon), was found in
Tunisians compared to Moroccans (12.8% vs. 21.7%, p =
ns), with a frequency similar to South Africans (Zulu 12%,
Cameroon 8.7%). The HLA-B*50 allele frequencies were
high in Tunisians (15.3%) as in Moroccans (11.6%) and
in accordance with previously reported information about
Tunisians of mixed origin (10%) [42]. Many allele groups
showed a high variability (4–6 alleles, A*02, A*30, B*15,
B*35, B*44). For instance, the HLA-B*15 group included
the -B*1503 and -B*1510 alleles, that are present at high
frequency in Sub-Saharan Africa. Overall, this data sup-
Table 2: Most common (frequency > 2%) HLA-A/B, Cw/B and Cw/B two-locus haplotypes in TU
Haplotype TUNISIANS Present in:*
HF Dx100 D' χ2 p
A/B
A*020101 B*5001 0.046 2.20 0.19 8.30 < 0.01 Caucasians, Hispanics, Tunisians1
A*020101 B*440201 0.037 2.90 0.74 38.00 < 0.001 Caucasians, Blacks
A*2301 B*5001 0.030 1.90 0.29 13.00 < 0.001
A*6802 B*1402 0.024 2.10 0.41 50.00 < 0.001 Mixed
A*020101 B*510101 0.024 1.50 0.33 8.70 < 0.05 Caucasians, Hispanics, Blacks, Tunisians1
Cw/B
Cw*0602 B*5001 0.122 9.10 0.84 120.00 < 0.001 Hispanics
Cw*0701 B*0801 0.047 3.80 0.69 65.00 < 0.001 Caucasians, Hispanics, Blacks, Tunisians1
Cw*0501 B*4402 0.041 3.90 0.87 22.00 < 0.001 Caucasians, Hispanics, Blacks, Tunisians1
Cw*0802 B*1402 0.037 3.40 0.66 120.00 < 0.001 Caucasians, Hispanics, Blacks, Tunisians1
Cw*0602 B*4501 0.034 2.40 0.65 22.00 < 0.001 Black
Cw*0702 B*070201 0.034 3.10 0.80 140.00 < 0.001 Caucasians, Blacks, Orientals
Cw*1502 B*510101 0.034 3.20 1.00 180.00 < 0.001 Caucasians, Hispanics, Tunisians1
Cw*0701 B*4901 0.027 2.30 0.99 54.00 < 0.001 Hispanics, Blacks, Tunisians1
Cw*0202 B*440301 0.027 2.20 0.33 32.00 < 0.001
Cw*1601 B*440301 0.027 2.40 0.58 59.00 < 0.001 Caucasians, Hispanics, Tunisians1
Cw*1202 B*520101 0.024 2.30 1.00 30.00 < 0.001 Hispanics, Orientals, Tunisians1
Cw*1701,03 B*4102 0.020 1.90 1.00 110.00 < 0.001 Very common
Cw*040101 B*3501 0.020 1.70 0.70 28.00 < 0.001 Caucasians, Hispanics, Blacks, Tunisians1
Cw*040101 B*5301 0.020 1.70 0.81 33.00 < 0.001 Hispanics, Blacks
Cw*120301 B*3801 0.020 1.90 1.00 130.00 < 0.001 Caucasians, Hispanic, Tunisians1
A/Cw
A*020101 Cw*0602 0.063 2.50 0.19 7.80 < 0.01
A*2301 Cw*0602 0.036 1.90 0.31 7.70 < 0.01
A*030101 Cw*0602 0.035 2.00 0.38 11.00 < 0.001
A*010101 Cw*040101 0.034 2.30 0.30 18.00 < 0.001 Blacks
A*020101 Cw*0501 0.033 2.50 0.62 28.00 < 0.001
In bold: haplotypes shared with ME. Other haplotypes (in italics) are shared but were not in linkage (p = ns) or were present at low frequency (< 
1.5%) in ME.
HF: haplotype frequency; SD: standard deviation; Dx100: linkage disequilibrium multiplied by 100; D': relative linkage disequilibrium; ChiSQ: chi-
square values
* According to the allele frequency worldwide population database [42,43].Journal of Translational Medicine 2007, 5:22 http://www.translational-medicine.com/content/5/1/22
Page 7 of 13
(page number not for citation purposes)
port the concept that Tunisians like other Maghrebian
populations maintain a Northern African genetic identity
which, however, includes traits derived from Sub-Saharan
African [29] as well as Spanish/European influence [27].
The higher level of differentiation present in Moroccans,
expressed by a reduced number of alleles compared to TU,
can be a genetic demonstration of a higher isolation of
this ethnic group.
Extended haplotype analysis
One hundred and eighty different haplotypes were calcu-
lated in Tunisians. Data on haplotypes are shown in table
2 (2 loci) and table 3 (3 loci). The most common class I
haplotypes were A*0201-B*5001-Cw*0602, shared by
Tunisians (haplotype frequency; hf = 0.054) and Moroc-
cans (hf = 0.040) and also present in Hispanics [43]
(Table 3), and A*0201-B*4402-Cw*05, present in His-
panics, Africans and Caucasians [43,42]. The A*2301-
B*5001-Cw*0602 was not found in other populations,
like the A*2301-B*5001 2-loci association. Many Cw-B
haplotypes, in strong linkage disequilibrium, are com-
mon haplotypes found in Hispanic, Caucasians, African
and African American (Black) populations, and have been
detected in other Tunisians [42]. Most haplotypes were
shared between Tunisians and Moroccans (Table 2 and 3,
in bold). Exceptions were represented by A*2301-
B*5001and B4403-Cw0202, not found in other popula-
tions, and there were also not present (A*2301-B*5001)
or present but in no significant linkage disequilibrium
(B4403-Cw0202) in Moroccans.
HLA class I frequencies in Tunisian patients with NPC
Of the 147 samples obtained from Tunisian subjects with
NPC only 135 HLA-A, 135 HLA-B and 136 HLA-Cw locus
typings could be carried out due to insufficient quantity or
quality of the recovered genomic DNA (Figure 1). The age
distribution of the cohort of NPC patients in this study
well reflected the recognized bimodal age distribution of
NPC in Tunisia. Indeed, the study included 32 patients
with NPC that were 25 year old or younger corresponding
to a frequency of 23% identical to the frequency reported
for this age group by Daoud J et al. [44].
To compare our results with previously reported studies
on NPC in Maghrebian populations, we first analyzed
allele frequencies at a low resolution (two digits) level
that more closely approximate the serological nomencla-
ture. Simple two by two comparison tables identified
HLA-B18, -B51 and -B57 to be associated with a predispo-
sition to develop NPC (Table 4). On the contrary, HLA-
B14 and Cw-08 were associated with a decreased risk of
developing NPC. The haplotype frequency was strongly
reduced in patients with NPC. At the phenotype level, 2 of
136 patients with NPC carried the HLA Cw*0802-B*1402
haplotype (1.47%) while 11 of 148 (7.4%) Tunisian con-
trols carried this haplotype (Fisher's test p2-value < 0.001).
With the exception of HLA-Cw-08, these findings specifi-
cally reproduced associations that had been previously
described in Maghrebian populations [22,24] Thus, these
results encouraged an in depth analysis of the HLA fre-
quencies in patients with NPC from Tunisia at the high
resolution level.
Extended haplotype analysis in Tunisian patients with 
NPC
The comparisons with the normal Tunisian and Moroccan
populations were performed only for haplotypes found in
Tunisians and/or patients with NPC (Table 5). Several
associations were noted between NPC prevalence and
HLA haplotypes. HLA-B*1801 was positively associated
with the prevalence of NPC at the allele and haplotype
level (specific NPC haplotype: A*020101-Cw*0701-
B*180101, absent in Tunisians and Moroccans). The hap-
lotype Cw*0501-B180101 was observed in Moroccans
and, therefore, it may be less specific; HLA-B*570101 was
also positively associated at the allele and haplotype level
(specific NPC haplotype: A*010101-Cw*0602-
B*570101, absent in Tunisians and Moroccans). Finally,
HLA B*510101 was associated with an increased risk of
developing NPC only at the allele but not the haplotype
level.
Table 3: Most common HLA-A, -Cw, -B haplotypes in TU and ME.
Haplotypes TU ME
HF SD HF SD
A0201 Cw0602 B5001 0.054 ± 0.013 0.040 ± 0.019
A0201 Cw0501, 03 B4402 0.034 ± 0.011 (0.008 ± 0.107)
A2301 Cw0602 B5001 0.024 ± 0.009 -
A0201 Cw040101 B4403 (0.007 ± 0.005) 0.032 ± 0.016
A2301 Cw040101 B4403 (0.007 ± 0.005) 0.032 ± 0.014
A0101 Cw0501, 03 B4402 - 0.032 ± 0.017
Standard deviations (SD) have been approximated by 400 bootstrap replicates. In bold: shared haplotypes. In parenthesis: haplotype present at low 
frequency in one of the two populations.Journal of Translational Medicine 2007, 5:22 http://www.translational-medicine.com/content/5/1/22
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SBT identified several sub-haplotypes including an HLA-
B*14 allele (Cw*0802-B*1402, A*6802-B*1402 and
A*1101-Cw*0802-B*1402) that appeared to be responsi-
ble for the negative relationship between HLA-B14 and
the prevalence of NPC in Tunisians. However, the most
striking negative association was observed between the
HLA-B*1402/Cw*0802 haplotype and the prevalence of
NPC (HF = 0.007 in patient with NPC compared to a HF
of 0.037 in Tunisians and 0.040 in Moroccans). In partic-
ular, all the HLA-Cw*08 alleles were identified by SBT as
HLA-Cw*0802 while HLA-B14, split this haplotype into 3
sub-haplotypes in which HLA-B*1402 occurred 11 times
(HF = 0.037) and HLA-B*1401 and B*1403 three times
each (none of them seen in patients with NPC).
There was a trend toward an age distribution bias with the
HLA class I loci associated with NPC predisposition occur-
ring more frequently in the younger age bracket (<25 year-
old patients). In particular, HLA-Cw*0602 was present at
a frequency of 44% (14 of 32) in 25 year old or younger
NPC patients compared to 16% (6 of 37) in patients who
had NPC diagnosed after the age of 50 (Fisher test p2-
value = 0.02). Similarly the HLA-B*5701/Cw*0602 hap-
lotype was present in 12% of cases below age 25, 6% of
cases between 25 and 50 and only 3% of cases above age
50. This trend was, however, not significant possibly
because of to the relatively small number of cases. Inter-
estingly, HLA-Cw*0602 and its extended haplotype HLA-
B*5701/Cw*0602 were particularly frequent among
young patients. Of 11 patients age 16 or younger, 7 (64%)
carried the HLA-Cw*0602 allele and 4 the extended hap-
lotype (37%) compared to a frequency of 25% and 4%
respectively in the older patients (Fisher's exact test p2-
value = 0.01 and 0.003 respectively). Interestingly, the
same haplotype was totally absent in the same age group
and it occurred only in one case among the 148 control
subjects studied. Thus, it is possible that this haplotype
may include a predisposition factor that may bear a par-
ticular influence on the penetrance of NPC before other
environmental factors could contribute to the onset of
NPC in later age groups.
Discussion
NPC is among common cancers the one whose prevalence
is most likely affected by a genetic predisposition that can
be uncovered through population studies. This seems to
particularly apply to the Southern Asian population
repeatedly shown to be affected at high incidence.
Although viral and environmental factors play an impor-
tant role in the ethio-pathogenesis of NPC, genetic factors
may also predispose as documented by several family
and/or case-control studies [45,46]. The short arm of the
human chromosome 6, is not the only genomic area that
has been implicated in NPC predisposition as a large fam-
ily study located a predisposition area in chromosome 3
[3]. However, many case-control studies pointed at HLA
class I as a genomic region strongly associated with the
prevalence of NPC in Southern Chinese [5-12,47-49]
Such associations may bear two possible explanations;
first the antigen presenting function of HLA molecules
may be responsible for an altered effectiveness of the
immune response against tumor associated antigens
expressed by NPC in individuals bearing different HLA
alleles [10]. This logical explanation is, however, chal-
lenged by the lack of candidate epitopic determinants
associated to particular HLA class I alleles that clearly
affect the natural history of NPC. In addition, most HLA
class I associations reported in Asian populations indi-
rectly support this concept since they are primarily associ-
ated with increased risk of developing NPC. This suggests
that lack of antigen presenting capacity may result in
reduced protection against the growth of NPC. For
instance, the HLA-A*0207 allele association reported by
Hildesheim et al. [10] in Taiwanese Chinese was
explained by suggesting a reduced antigen presentation
potential of this allele compared with other HLA-A*02
alleles present in the same population such as HLA-
A*0201 which are not associated with higher prevalence
of NPC. Similarly, the higher prevalence of HLA-A*0207
in Asians compared to Caucasians [10] may also explain
the higher prevalence of the disease in Asian populations.
However, associations of HLA phenotypes with increase
prevalence of NPC are difficult to attribute to a single
Table 4: Significant (Fisher's test p2 < 0.05) allele associations with NPC
HLA allele NPC cases (%) Control subjects (%) OR 95% CI P Ref
Cw08 1.10 (3/272) 5.74 (17/296) 0.18 0.052 – 0.618 0.003 -
B14 0.74 (2/270) 7.43 (22/296) 0.09 0.021 – 0.388 0.0001 [22]
B14-Cw08 0.74 (2/270) 5.74 (17/296) 0.12 0.027 – 0.519 0.001 -
B51 11.11 (30/270) 5.74 (17/296) 1.98 1.067 – 3.679 0.025 [22]
B57 3.70 (10/270) 0.68(2/296) 5.48 1.190 – 25.224 0.017 [22]
B18 6.67 (18/270) 2.36 (7/296) 2.85 1.173 – 6.941 0.014 [24]
N.B. 136 typing could be performed for the HLA-Cw locus in patient with NPC while only 135 could be performed in the same patients for the 
HLA-A and -B loci.Journal of Translational Medicine 2007, 5:22 http://www.translational-medicine.com/content/5/1/22
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Table 5: Comparison of the most common (frequency > 2%) HLA-A/B, Cw/B and A/Cw two-loci haplotypes in Tunisians, Tunisian NPC 
patients and in ME
Haplotype TUNISIANS NPC TUNISIANS ME
HF Dx100 D' χ2 p HF Dx100 D' χ2 pH F χ2 p
A/B
A*020101 B*5001 0.045 2.20 0.20 8.9 < 0.01 0.044 2.70 0.33 16 < 0.001 0.029 3.50 NS
A*020101 B*440201 0.037 2.90 0.74 40.0 < 0.001 Not
present
0 . 0 2 20 . 2 4N S
A*2301 B*5001 0.030 2.00 0.29 14.0 < 0.001 (0.011) Not
present
A*6802 B*1402 0.023 2.00 0.41 49.0 < 0.001 Not
present
(0.015)
A*020101 B*510101 0.020 1.10 0.25 5.1 < 0.05 (0.018) (0.015)
A*010101 B*570101 (0.003) 0.022 1.80 0.62 23 < 0.001 (0.015)
A*020101 B*180101 (0.010) 0.030 1.80 0.33 10 < 0.01 0.022 NS
A*020101 B*440301 (0.013) 0.033 1.80 0.24 7.6 < 0.01 0.029 NS
A*2902 B*440301 (0.012) 0.021 1.60 0.29 15 < 0.001 Not
present
A*3402 B*0801 (0.006) 0.022 2.00 0.72 58 < 0.001 Not
present
Cw/B
Cw*0701 B*0801 0.047 3.90 0.70 68.00 < 0.001 0.056 4.40 0.75 58 < 0.001 0.089 55.97 < 0.001
Cw*040101 B*4403 (0.016) 0.047 3.50 0.45 36 < 0.001 0.081 31.17 < 0.001
Cw*0602 B*5001 0.120 9.10 0.84 120.00 < 0.001 0.081 6.20 0.77 76 < 0.001 0.073 42.62 < 0.001
Cw*1701,03 B*4102 0.020 1.90 1.00 120.00 < 0.001 0.026 2.50 1.00 160 < 0.001 0.065 124.00 < 0.001
Cw*0701 B*4901 0.027 2.30 1.00 57.00 < 0.001 0.041 3.40 0.99 57 < 0.001 0.056 34.40 < 0.001
Cw*0802 B*1402 0.037 3.40 0.67 130.00 < 0.001 (0.007) 0.040 87.08 < 0.001
Cw*040101 B*3501 0.020 1.70 0.71 30.00 < 0.001 Not
present
0.040 30.68 < 0.001
Cw*0501 B*4402 0.040 3.80 0.85 22.00 < 0.001 (0.018) 1.70 0.53 61 < 0.001 0.040 25.79 < 0.001
Cw*0501 B*1801 Not
present
0.022 2.00 0.52 43 < 0.001 0.032 36.37 < 0.001
Cw*0602 B*4501 0.033 2.30 0.64 22.00 < 0.001 (0.011) 0.81 0.67 7.8 < 0.01 0.032 13.03 < 0.001
Cw*0702 B*070201 0.033 3.10 0.82 150.00 < 0.001 (0.018) 1.80 0.97 130 < 0.001 0.025 92.21 < 0.001
Cw*0202 B*440301 0.027 2.20 0.33 34.00 < 0.001 (0.012) 0.032 NS
Cw*1502 B*510101 0.033 3.20 1.00 180.00 < 0.001 0.044 4.10 1.00 140 < 0.001 (0.016)
Cw*1601 B*440301 0.027 2.40 0.59 62.00 < 0.001 0.022 1.90 0.51 30 < 0.001 (0.008)
Cw*1202 B*520101 0.023 2.30 1.00 30.00 < 0.001 0.030 2.90 0.89 220 < 0.001 Not
present
Cw*040101 B*5301 0.020 1.70 0.83 35.00 < 0.001 0.037 3.20 1.00 68 < 0.001 (0.008)
Cw*120301 B*3801 0.020 1.90 1.00 140.00 < 0.001 (0.018) Not
present
Cw*0602 B*1302 (0.017) 0.026 2.10 1.00 30 < 0.001 Not
present
Cw*020204 B*1503 (0.014) 0.033 3.20 1.00 280 < 0.001 (0.016)
Cw*0701 B*180101 Not
present
0.037 2.60 0.46 21 < 0.001 (0.008)
Cw*0602 B*570101 (0.003) 0.033 2.70 1.00 40 < 0.001 (0.008)
A/Cw
A*020101 Cw*0602 0.061 2.40 0.18 7.60 < 0.01 0.023 NS 0.077 11.00 < 0.001
A*030101 Cw*0602 0.035 2.10 0.40 12.00 < 0.001 0.033 1.90 0.32 9.4 < 0.01 Not
present
A*010101 Cw*040101 0.033 2.20 0.29 17.00 < 0.001 (0.007) Not
present
A*020101 Cw*0501,03 0.032 2.40 0.63 28.00 < 0.001 0.022 1.50 0.46 12 < 0.001 (0.012)
A*2301 Cw*0602 0.032 1.60 0.27 6.50 < 0.05 (0.016) Not
present
A*010101 Cw*0602 Not
present
0.041 1.60 0.15 3.9 NS 0.026 NSJournal of Translational Medicine 2007, 5:22 http://www.translational-medicine.com/content/5/1/22
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allele considering the high frequency of heterozygosity
and the co-dominant expression of the three HLA class I
loci aimed at broadening the antigen presenting repertoire
of each individual.
An alternative explanation for the association between
HLA and the prevalence of NPC attributes a broader sig-
nificance of HLA class I genes as markers for other predis-
position factors genetically controlled within a locus in
close linkage disequilibrium [21]. For instance, even in
Hildesheim's report, the extended haplotype HLA-
A*0207/HLA-B*4601 was characterized by a higher odds
ratio to develop NPC than the HLA-A*0207 allele alone
suggesting a more complex genetic explanation for such
association than the displacement by the HLA-A*0207
allele of other HLA class I alleles belonging to the HLA-
A*02 family. In addition, our and others' experiences do
not suggest strong differences in epitope binding and anti-
gen presentation between HLA-A*0201 (the prototypic
Caucasian HLA-A*02 allele) and HLA-A*0207. These alle-
les differ only by one amino acid substitution from a Tyro-
sine to a Cysteine in position 99 within the binding
groove of the HLA molecule. This substitution does not
seem to significantly affect binding and presentation of
canonical HLA-A*0201-associated epitopes [50-52] as
well as EBV-associated epitopes [53]. Finally, lack of anti-
gen presentation capacity by a specific HLA class I allele
should be compensated by other alleles expressed by the
same individual; therefore, favouring homozygosity of
the unfavourable allele in affected individuals. However,
most reports do not suggest higher homozygosity values
in high prevalence populations suggesting lack of balanc-
ing selection. Thus, dominant genetic traits directly
related to oncogenesis may play a more important role
than HLA class I alleles which are co-dominantly
expressed.
Maghrebs have been less exhaustively studied. However,
serological analyses observed positive associations
between NPC and HLA class I alleles. These include
increased frequency of HLA-B5 in Algerians (38.2% vs
24.4%) [22], HLA-B13 in Tunisians (15.5% vs 4) [23] and
HLA-B18 in Moroccans (relative risk = 4.14) [24]. In addi-
tion, negative associations have been reported such as
HLA-Aw33, -B14 in Algerians with NPC. However, after
correction for the number of specificities tested, these dif-
ferences were not statistically significant and were not pur-
sued further. HLA-A*3301 and HLA-B*1402 have
subsequently been recognized to belong to the same
ancestral haplotype [25] suggesting that this haplotype
may harbor more relevance to NPC than previously recog-
nized. This impression was supported also by the identifi-
cation of a negative association between HLA-A23
(known to belong to the extended HLA-A*2301/HLA-
B*1403 haplotype [26]) and the prevalence of NPC [23].
This observation converges toward the relevance of HLA-
B14 related haplotypes which may bear protective effects
against NPC in North Africans. Moreover, Dardari R et al.
[24] reported a significantly lower frequency of the HLA-
A9 serologic family alleles in NPC patients compared with
controls. Since the latter study did not provide molecular
resolution, we can only speculate that the reduced fre-
quency of HLA-A9 reflected a lower frequency of the HLA-
A*2301/HLA-B*1403 haplotype since HLA-A23 is part of
the HLA-A9 serological family. Thus, previous studies in
Maghrebians suggested that HLA-B14 and HLA-A alleles
linked to the HLA-B14 serological family may be under-
represented in patients with NPC compared with normal
controls. Conversely, HLA-B5, -B13 and -B18 could be
associated with increased risk of NPC.
Low resolution (two digits level) analysis of allele fre-
quency in our study quite remarkably and specifically
confirmed previous positive associations described
between NPC and HLA class I alleles in Berber popula-
tions. Both HLA-B*18 and -B*51 (the latter representing
a split of the serologically-defined HLA-B5 family) were
confirmed by our study (Table 4). In addition, a novel
association was observed between HLA-B-57 (belonging
to the HLA-B17 serological family) and the prevalence of
NPC. Only the positive association observed in Tunisians
between HLA-B13 and NPC prevalence was not repro-
duced by this study [23]. Negative associations were also
identified by this study of which only HLA-B*14 (OR =
0.09, Fisher's test p-2 value = 0.0001) strongly reproduced
previous findings while no association was noted with
HLA-A*23 nor HLA-A*33. Interestingly, however,
another strong negative association was noted between
HLA-Cw*0802 and NPC (OR = 0.18, Fisher's test p-2
value = 0.003). This is of particular significance because
A*010101 Cw*0701 0.023 NS 0.037 1.60 0.14 4.2 NS (0.016)
A*020101 Cw*040101 (0.014) 0.037 1.40 0.13 3.3 NS 0.040 NS
A*020101 Cw*0701 0.023 NS 0.036 NS 0.020 NS
A*2902 Cw*1601 (0.010) 0.022 1.90 0.52 48 < 0.001 Not
present
A*3402 Cw*0701 (0.007) 0.022 1.70 0.69 20 < 0.001 (0.016)
HF: haplotype frequency; SD: standard deviation; Dx100: linkage disequilibrium multiplied by 100; D': relative linkage disequilibrium; χ2: chi-square 
values In bold: alleles involved in NPC. In parenthesis: haplotypes present at low frequency (< 2%).
Table 5: Comparison of the most common (frequency > 2%) HLA-A/B, Cw/B and A/Cw two-loci haplotypes in Tunisians, Tunisian NPC 
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both HLA-B*1402 and HLA-Cw*0802 belong to the same
ancestral haplotype which was present not only in Tuni-
sians but also Moroccan Berbers but practically absent in
Tunisian patients with NPC (OR = 0.12, Fisher's test p-2
value = 0.001). This strong negative association suggests
that this haplotype may bear a locus in strong linkage dis-
equilibrium with these HLA alleles with dominant protec-
tive effects against the onset of NPC in North Africans
such as a tumor suppressor gene with stronger stability in
this phenotype. Since protective alleles have also been
described in Asian populations (such as HLA-A11) [13], it
could be postulated that some HLA alleles may bear
immunological functions facilitating the immune surveil-
lance against NPC. However, there is no known func-
tional similarity between alleles described in Chinese and
North Africans to support this hypothesis suggesting that
other factors may bear on this predisposition. Indeed, in
Asian populations, micro-satellite analyses within the
short arm of Chromosome 6 identified associations
between putative loci and NPC prevalence that are
stronger than those with HLA class I alleles [12]. Hu C-C
et al. [54] using high-resolution micro satellite mapping
recently described a carcinoma-susceptibility locus
located in a segment of Chromosome 6p21.3 containing
the class I loci. Similarly, Nh SP et al. [55] concluded that
an HLA-related recessive mutation is responsible for the
prevalence of NPC in Chinese. Finally, Tian W et al. [56]
identified in the Southern Chinese Han population a pos-
itive association between a predisposition to develop NPC
and exon 5 of the MICA-STR encoded within the HLA
class I region. Moreover, a recent meta-analysis of chro-
mosomal aberrations associated with NPC [57] identified
a small region in Chromosome 6p21.2-p23 that is fre-
quently amplified in NPC and contains various candidate
genes that may be responsible for NPC [58]. Thus, our
findings suggest that there are haplotypes within or close
to HLA class I region, particularly the HLA-B and -C loci
that may bear genetic characteristics favoring or protecting
against the onset of NPC in Tunisian populations at risk.
This information may help identify individuals belonging
to different ethnic groups whose genetic risk to develop
NPC could be marked by HLA class I haplotypes. These
prototypic phenotypes could be scanned with novel high
throughput technologies covering genomic areas in high
linkage disequilibrium with such haplotypes. Since the
analysis of the Tunisian control population did not iden-
tify differences between Tunisians and Moroccans, con-
sidering that a common Berber substratum is shared by
North African countries [59-63], it is possible that our
findings could be relevant to the other Northern African
populations justifying the extension of future studies to
Moroccans and Algerians [24].
Some of the alleles discussed by this study have been asso-
ciated with other pathologies. HLA-B*1403 is the pre-
dominant allele in patients affected by ankylosing
spondylitis from West Africa, where HLA-B*27 is uncom-
mon [64]. HLA-B*51 and HLA-B*15 alleles have been
associated with Behcet disease [65], B*44, B*51, B*57,
B*15 with HPV infection and protection/susceptibility to
in cervical carcinoma [66]. The present study, may offer
novel insight on the molecular genetics of this region that
may influence disease, although obvious relationships
between the information presented and it causality is still
missing.
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